Martha Lopez-Yurda

11PUBLICATIONS
112CO-AUTHORS
Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Sep 17, 2026
Pre-existing immunity and hrHPV status determine immunotherapy response in advanced penile cancer: biomarkers and overall survival in the PERICLES trial.

|Feb 03, 2026
PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

Rosie A B Voorthuis, Mafalda Oliveira, Annelot G J van Rossum

|Jan 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen

|Apr 14, 2025
Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.

S L Aronson, B Thijssen, M Lopez-Yurda

|Sep 16, 2024
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

Iris Nederlof, Olga I Isaeva, Manon de Graaf

|Sep 14, 2024
Histopathological response to chemotherapy and survival of mucinous type gastric cancer.

Irene A Caspers, Astrid E Slagter, Pauline A J Vissers

Pageof 2

Frequent Collaborators

4 joint publications

Christian U Blank

3 joint publications

Annegien Broeks

3 joint publications

Joyce Sanders

3 joint publications

Lodewyk F A Wessels